8-K: Ekso Bionics Reports First Quarter 2025 Financial Results, Revenue Declines but Cash Burn Improves

Ekso Bionics announced its Q1 2025 financial results, showing a decrease in revenue but improved operating cash burn and strategic partnerships.

Summary

• Ekso Bionics reported revenue of $3.4 million for the quarter ended March 31, 2025, compared to $3.8 million for the same period in 2024.
• The decrease in revenue was primarily due to lower sales of legacy EksoNR devices, partially offset by higher Ekso Indego Personal device sales.
• Gross profit for Q1 2025 was $1.8 million, with a gross margin of approximately 53.5%, compared to $2.0 million and 51.9% respectively in Q1 2024.
• The company's net loss applicable to common stockholders for Q1 2025 was $2.9 million, or $0.12 per share, compared to a net loss of $3.4 million, or $0.20 per share, for the same period in 2024.
• Net cash used in operations for Q1 2025 was $2.0 million, compared to $3.5 million for the same period in 2024, representing a 43% improvement in operating cash burn.
• As of March 31, 2025, Ekso Bionics had cash and restricted cash of $8.1 million.
• The company named National Seating & Mobility (NSM) as its exclusive Ekso Indego Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry.
• Bionic Prosthetics & Orthotics Group (Bionic P&O) was named as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industry.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue decreased, the company improved its cash burn and secured strategic partnerships, indicating potential for future growth. The decrease in net loss also contributes to the moderately positive outlook.

Positives

• Operating cash burn improved by 43%, decreasing from $3.5 million in Q1 2024 to $2.0 million in Q1 2025.
• Gross margin increased from 51.9% in Q1 2024 to 53.5% in Q1 2025 due to cost savings in supply chain and a reduction in service costs.
• Net loss decreased from $3.4 million in Q1 2024 to $2.9 million in Q1 2025.
• The company secured partnerships with NSM and Bionic P&O to expand access to Ekso Indego Personal devices.
• The company strengthened its financial position with $3.8 million in net proceeds from the exercise of warrants.

Negatives

• Revenue decreased from $3.8 million in Q1 2024 to $3.4 million in Q1 2025, primarily due to lower sales of legacy EksoNR devices.
• Gross profit decreased from $2.0 million in Q1 2024 to $1.8 million in Q1 2025.
• General and administrative expenses increased from $2.3 million in Q1 2024 to $2.6 million in Q1 2025, primarily due to an impairment loss of an intangible asset and higher legal and audit costs.

Risks

• The company's inability to obtain adequate financing to fund and grow operations.
• The company's inability to successfully collaborate with its network of existing neuro-rehabilitation facilities, physicians, and DMEs in seeking CMS reimbursements.
• The company's inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels.
• The company's ability to raise funds to operate and grow its business.
• The company's inability to obtain insurance coverage beyond CMS.
• The company's inability to obtain additional indications of use for its devices.
• The significant length of time and resources associated with the development of the company's products.
• The company's failure to achieve broad market acceptance of the company's products.
• The failure of the company's sales and marketing efforts or of partners to market the company's products effectively.
• Adverse results in future clinical studies of the company's medical device products.
• The failure of the company to obtain or maintain patent protection for the company's technology.
• The failure of the company to obtain or maintain regulatory approval to market the company's medical devices.
• Lack of product diversification.
• Existing or increased competition.
• Disruptions in the company's supply chain.
• The company's failure to implement the company's business plans or strategies.

Future Outlook

The company expects to see increased contribution from Personal Health products in 2025 as a result of new partnerships.

Management Comments

• Scott Davis, the Company's Chief Executive Officer, stated that the company has significantly expanded access to Ekso Indego Personal via potentially transformative partnerships with two key leaders within their respective industries.

Industry Context

Ekso Bionics' partnerships with NSM and Bionic P&O reflect a strategy to expand market reach through established distribution networks in the CRT and orthotics/prosthetics industries, which are experiencing growth.

Comparison to Industry Standards

• Comparing Ekso Bionics to competitors like ReWalk Robotics and Myomo, Ekso's revenue is within the same order of magnitude, but the focus on both medical and industrial applications differentiates it.
• ReWalk Robotics, another exoskeleton company, has also focused on securing distribution partnerships to expand market access.
• Myomo, which focuses on myoelectric orthotics, has seen growth in its direct billing and reimbursement efforts, a strategy Ekso is also pursuing.
• The 53.5% gross margin is comparable to other medical device companies, but the relatively low revenue base means that achieving profitability remains a challenge.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the improved cash burn and strategic partnerships.
• Employees may benefit from the company's growth initiatives and new partnerships.
• Customers will have increased access to Ekso Indego Personal devices through the new distribution agreements.
• Suppliers may see increased demand for components as production ramps up to meet the needs of the new partnerships.
• Creditors will be reassured by the improved cash burn and the company's efforts to strengthen its financial position.

Next Steps

• Ekso Bionics will hold a conference call to discuss the financial results and recent business developments.
• The company will focus on integrating the new distribution partnerships to drive sales of Ekso Indego Personal devices.
• The company will continue to execute on its growth strategy.

Key Dates

Keywords

Ekso Bionics, exoskeleton, financial results, Q1 2025, revenue, gross profit, net loss, cash burn, EksoNR, Ekso Indego Personal, NSM, Bionic P&O, medical devices, robotics